1. Home
  2. NUVL vs MGM Comparison

NUVL vs MGM Comparison

Compare NUVL & MGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$104.15

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

Logo MGM Resorts International

MGM

MGM Resorts International

HOLD

Current Price

$36.55

Market Cap

9.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
MGM
Founded
2017
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
9.5B
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
NUVL
MGM
Price
$104.15
$36.55
Analyst Decision
Strong Buy
Hold
Analyst Count
16
15
Target Price
$134.75
$42.88
AVG Volume (30 Days)
543.5K
3.9M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.76
Revenue
N/A
$9,809,663,000.00
Revenue This Year
N/A
$1.80
Revenue Next Year
$1,235.73
$1.61
P/E Ratio
N/A
$49.07
Revenue Growth
N/A
N/A
52 Week Low
$63.56
$28.12
52 Week High
$113.02
$40.16

Technical Indicators

Market Signals
Indicator
NUVL
MGM
Relative Strength Index (RSI) 54.55 48.65
Support Level $97.63 $35.82
Resistance Level $107.08 $37.94
Average True Range (ATR) 3.66 1.28
MACD 0.56 -0.05
Stochastic Oscillator 72.02 28.90

Price Performance

Historical Comparison
NUVL
MGM

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About MGM MGM Resorts International

MGM Resorts is the largest resort operator on the Las Vegas Strip with 37,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 56% of total EBITDAR in 2025. MGM also owns US regional assets, which represented a low 20s share of 2025 EBITDAR (MGM's Macao EBITDAR was 23% of the total in 2025). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a second property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.

Share on Social Networks: